Annovis Bio, Inc. (ANVS) Stock

About Annovis Bio, Inc.

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.

Annovis Bio, Inc. is led by CEO Maria L. Maccecchini, employs 8 people, headquartered in US, publicly traded since 2020.

Annovis Bio, Inc. (ANVS) stock trades at $1.00 with a market capitalization of $42.65M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.56, reflecting a net loss over the last twelve months, a negative price-to-book of -8.82, reflecting negative shareholders' equity, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.95 and $5.50, and currently trades 81.8% below its 52-week high.

On profitability, Annovis Bio, Inc. generates a return on equity (ROE) of -685.96% (negative, reflecting a net loss), return on capital employed of -315.92%.

Official website: www.annovisbio.com

Annovis Bio, Inc. by the numbers, 2017–2025

Between 2017 and 2025 Annovis Bio, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-29.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-50.0M.

Borrowings stand at $0, cash on hand is $19.0M, cash from operations was $-26.0M in the latest year, positive in 0 of the last 9.

Return on equity has averaged 26.1% over five years, and was -170.6% in the most recent year.

The share price itself has compounded at -54.8% a year over five years, -50.0% over three, -36.3% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Annovis Bio, Inc. (ANVS) — frequently asked questions